×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CSTL – castle biosciences, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CSTL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/23
09:17 pm
cstl
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript [Seeking Alpha]
Neutral
Report
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript [Seeking Alpha]
3/23
06:54 pm
cstl
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk [Yahoo! Finance]
Neutral
Report
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk [Yahoo! Finance]
3/21
12:35 am
cstl
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets [Yahoo! Finance]
Medium
Report
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets [Yahoo! Finance]
3/13
11:45 am
cstl
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB [Yahoo! Finance]
Low
Report
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB [Yahoo! Finance]
3/13
11:02 am
cstl
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
Low
Report
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
3/13
03:53 am
cstl
SciBase: Interim report [Yahoo! Finance]
Low
Report
SciBase: Interim report [Yahoo! Finance]
3/9
07:32 am
cstl
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk [Yahoo! Finance]
Low
Report
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk [Yahoo! Finance]
3/9
07:00 am
cstl
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Low
Report
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2026
04:05 pm
cstl
castle biosciences, inc. - common stock
BEAT
Report
-7.2%
castle biosciences, inc. - common stock
11/3/2025
04:07 pm
cstl
castle biosciences, inc. - common stock
BEAT
Report
21.7%
castle biosciences, inc. - common stock
8/4/2025
04:05 pm
cstl
castle biosciences, inc. - common stock
BEAT
Report
32.8%
castle biosciences, inc. - common stock
5/5/2025
04:06 pm
cstl
castle biosciences, inc. - common stock
MISS
Report
-10.7%
castle biosciences, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/19
04:21 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Mar 17 Filed by: MAETZOLD DEREK J
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Mar 17 Filed by: MAETZOLD DEREK J
3/17
04:38 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Mar 13 Filed by: MAETZOLD DEREK J
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Mar 13 Filed by: MAETZOLD DEREK J
3/16
04:08 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Mar 12 Filed by: Juvenal Tobin W
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Mar 12 Filed by: Juvenal Tobin W
3/13
04:10 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Mar 11 Filed by: MAETZOLD DEREK J
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Mar 11 Filed by: MAETZOLD DEREK J
3/12
04:39 pm
cstl
Form 144 CASTLE BIOSCIENCES INC Filed by: Juvenal Tobin W
Low
Report
Form 144 CASTLE BIOSCIENCES INC Filed by: Juvenal Tobin W
3/11
04:52 pm
cstl
Form 144 CASTLE BIOSCIENCES INC Filed by: MAETZOLD DEREK J
Medium
Report
Form 144 CASTLE BIOSCIENCES INC Filed by: MAETZOLD DEREK J
3/9
04:14 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Mar 05 Filed by: Stokes Frank
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Mar 05 Filed by: Stokes Frank
3/9
04:13 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Mar 05 Filed by: Cole G Bradley
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Mar 05 Filed by: Cole G Bradley
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/11
Q3/2019 9/30/2019 EPS 0.050 ZacksConsensus -0.310 ActVsEst 0.360 - Beat
19.6%
3/16 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 18.9%
8/22 Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019 14.1%
4/6 Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference 13.4%
10/29 Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting 11.0%
7/31 Form 4 CASTLE BIOSCIENCES INC For: Jul 29 Filed by: Cook Joseph C. III 10.9%
12/19 Form 8-K CASTLE BIOSCIENCES INC For: Dec 13 8.6%
10/31 Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk 8.4%
10/29 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
1/3 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.6%
3/16 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 18.9%
8/22 Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019 14.1%
4/6 Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference 13.4%
10/29 Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting 11.0%
7/31 Form 4 CASTLE BIOSCIENCES INC For: Jul 29 Filed by: Cook Joseph C. III 10.9%
12/19 Form 8-K CASTLE BIOSCIENCES INC For: Dec 13 8.6%
10/31 Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk 8.4%
10/29 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
1/3 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.6%
TOP News Decliners
3/11
Castle Biosciences (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $37.00 to $38.00. They now have an "outperform" rating on the stock.
-12.7%
10/21 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%
9/6 Castle Biosciences (NASDAQ: CSTL) was given a new $33.00 price target on by analysts at Leerink Swann. They now have a "buy" rating on the stock. -11.5%
3/11 Castle Biosciences Inc (CSTL) Q4 2019 Earnings Call Transcript [The Motley Fool] -11.5%
2/25 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 -9.4%
2/21 Form 4 CASTLE BIOSCIENCES INC For: Feb 19 Filed by: HealthQuest Venture Management, L.L.C. -7.4%
1/13 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -7.0%
9/3 Form 8-K CASTLE BIOSCIENCES INC For: Sep 03 -6.9%
10/18 Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node -5.7%
7/29 Form S-8 CASTLE BIOSCIENCES INC -5.3%
10/21 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%
9/6 Castle Biosciences (NASDAQ: CSTL) was given a new $33.00 price target on by analysts at Leerink Swann. They now have a "buy" rating on the stock. -11.5%
3/11 Castle Biosciences Inc (CSTL) Q4 2019 Earnings Call Transcript [The Motley Fool] -11.5%
2/25 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 -9.4%
2/21 Form 4 CASTLE BIOSCIENCES INC For: Feb 19 Filed by: HealthQuest Venture Management, L.L.C. -7.4%
1/13 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -7.0%
9/3 Form 8-K CASTLE BIOSCIENCES INC For: Sep 03 -6.9%
10/18 Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node -5.7%
7/29 Form S-8 CASTLE BIOSCIENCES INC -5.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: